SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?


To: David S. who wrote (769)8/24/1998 3:10:00 PM
From: Mark T Warren  Read Replies (1) | Respond to of 965
 
More good news...Who would be selling here?

Eli Lilly & Co. (LLY) 74 9/16 +3/8: Lehman Brothers reaffirms "buy" rating on pharmaceutical concern following positive ReoPro data results presented at the 20th Congress of the European Society of Cardiology; has a price target of $107 a share.....

Centocor Inc. (CNTO) 39 1/4 +1 1/2: --UPDATE-- Lehman Brothers reaffirms "buy" rating on biopharmaceutical concern after positive data results on ReoPro; believes data will drive demand for ReoPro; has a $65 price target.....